Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
AstraZeneca
Boehringer Ingelheim
Merck
Harvard Business School

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR RIOMET ER


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Riomet Er

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00087516 ↗ Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) Completed Merck Sharp & Dohme Corp. Phase 3 2004-06-01 The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Center for Research Resources (NCRR) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
NCT00443755 ↗ Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2005-08-01 The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Riomet Er

Condition Name

Condition Name for Riomet Er
Intervention Trials
Insulin Resistance 4
Type 2 Diabetes Mellitus 4
Type 2 Diabetes 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Riomet Er
Intervention Trials
Diabetes Mellitus 11
Diabetes Mellitus, Type 2 7
Insulin Resistance 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Riomet Er

Trials by Country

Trials by Country for Riomet Er
Location Trials
United States 146
Canada 4
Mexico 4
South Africa 4
Puerto Rico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Riomet Er
Location Trials
Pennsylvania 7
California 7
Ohio 7
North Carolina 6
Utah 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Riomet Er

Clinical Trial Phase

Clinical Trial Phase for Riomet Er
Clinical Trial Phase Trials
Phase 4 9
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Riomet Er
Clinical Trial Phase Trials
Completed 18
Recruiting 7
Active, not recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Riomet Er

Sponsor Name

Sponsor Name for Riomet Er
Sponsor Trials
National Cancer Institute (NCI) 6
Merck Sharp & Dohme Corp. 4
Takeda 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Riomet Er
Sponsor Trials
Other 43
NIH 19
Industry 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Colorcon
McKinsey
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.